Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products.

Q2 Biochemistry, Genetics and Molecular Biology
Clinical and Vaccine Immunology Pub Date : 2017-08-04 Print Date: 2017-08-01 DOI:10.1128/CVI.00186-16
Khandra T Sears, Sharon M Tennant, Mardi K Reymann, Raphael Simon, Nicky Konstantopoulos, William C Blackwelder, Eileen M Barry, Marcela F Pasetti
{"title":"Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products.","authors":"Khandra T Sears, Sharon M Tennant, Mardi K Reymann, Raphael Simon, Nicky Konstantopoulos, William C Blackwelder, Eileen M Barry, Marcela F Pasetti","doi":"10.1128/CVI.00186-16","DOIUrl":null,"url":null,"abstract":"<p><p>Diarrhea is a common illness among travelers to resource-limited countries, the most prevalent attributable agent being enterotoxigenic <i>Escherichia coli</i> (ETEC). At this time, there are no vaccines licensed specifically for the prevention of ETEC-induced traveler's diarrhea (TD), and this has propelled investigation of alternative preventive methods. Colostrum, the first milk expressed after birthing, is rich in immunoglobulins and innate immune components for protection of newborns against infectious agents. Hyperimmune bovine colostrum (HBC) produced by immunization of cows during gestation (and containing high levels of specific antibodies) is a practical and effective prophylactic tool against gastrointestinal illnesses. A commercial HBC product, Travelan, is available for prevention of ETEC-induced diarrhea. Despite its demonstrated clinical efficacy, the underlying immune components and antimicrobial activity that contribute to protection remain undefined. We investigated innate and adaptive immune components of several commercial HBC products formulated to reduce the risk of ETEC-induced diarrhea, including Travelan and IMM-124E, a newer product that has broader gastrointestinal health benefits. The immune components measured included total and ETEC-specific IgG, total IgA, cytokines, growth factors, and lactoferrin. HBC products contained high levels of IgG specific for multiple ETEC antigens, including O-polysaccharide 78 and colonization factor antigen I (CFA/I) present in the administered vaccines. Antimicrobial activity was measured <i>in vitro</i> using novel functional assays. HBC greatly reduced ETEC motility in soft agar and exhibited bactericidal activity in the presence of complement. We have identified immune components and antimicrobial activity potentially involved in the prevention of ETEC infection by HBC <i>in vivo</i>.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00186-16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/8/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Diarrhea is a common illness among travelers to resource-limited countries, the most prevalent attributable agent being enterotoxigenic Escherichia coli (ETEC). At this time, there are no vaccines licensed specifically for the prevention of ETEC-induced traveler's diarrhea (TD), and this has propelled investigation of alternative preventive methods. Colostrum, the first milk expressed after birthing, is rich in immunoglobulins and innate immune components for protection of newborns against infectious agents. Hyperimmune bovine colostrum (HBC) produced by immunization of cows during gestation (and containing high levels of specific antibodies) is a practical and effective prophylactic tool against gastrointestinal illnesses. A commercial HBC product, Travelan, is available for prevention of ETEC-induced diarrhea. Despite its demonstrated clinical efficacy, the underlying immune components and antimicrobial activity that contribute to protection remain undefined. We investigated innate and adaptive immune components of several commercial HBC products formulated to reduce the risk of ETEC-induced diarrhea, including Travelan and IMM-124E, a newer product that has broader gastrointestinal health benefits. The immune components measured included total and ETEC-specific IgG, total IgA, cytokines, growth factors, and lactoferrin. HBC products contained high levels of IgG specific for multiple ETEC antigens, including O-polysaccharide 78 and colonization factor antigen I (CFA/I) present in the administered vaccines. Antimicrobial activity was measured in vitro using novel functional assays. HBC greatly reduced ETEC motility in soft agar and exhibited bactericidal activity in the presence of complement. We have identified immune components and antimicrobial activity potentially involved in the prevention of ETEC infection by HBC in vivo.

Abstract Image

Abstract Image

Abstract Image

抗腹泻肠毒性大肠杆菌高免疫牛初乳产品中的生物活性免疫成分。
腹泻是前往资源有限国家的旅行者的常见病,最常见的致病菌是肠毒性大肠杆菌(ETEC)。目前,还没有专门用于预防 ETEC 引起的旅行者腹泻 (TD) 的疫苗,这推动了对其他预防方法的研究。初乳是婴儿出生后分泌的第一口乳汁,富含免疫球蛋白和先天性免疫成分,可保护新生儿免受感染。奶牛在妊娠期间通过免疫接种产生的高免疫牛初乳(含有高水平的特异性抗体)是预防胃肠道疾病的一种实用而有效的工具。商用 HBC 产品 Travelan 可用于预防 ETEC 引起的腹泻。尽管该产品的临床疗效已得到证实,但其潜在的免疫成分和抗菌活性仍未确定。我们研究了几种为降低 ETEC 引起的腹泻风险而配制的商业 HBC 产品的先天性免疫成分和适应性免疫成分,包括 Travelan 和 IMM-124E(一种具有更广泛胃肠道健康益处的新型产品)。测量的免疫成分包括总 IgG 和 ETEC 特异性 IgG、总 IgA、细胞因子、生长因子和乳铁蛋白。HBC 产品中含有高水平的针对多种 ETEC 抗原的特异性 IgG,包括 O 多糖 78 和定植因子抗原 I (CFA/I),这些抗原存在于接种的疫苗中。抗菌活性是通过新型功能测定法在体外进行测定的。HBC 大大降低了 ETEC 在软琼脂中的运动能力,并在补体存在的情况下表现出杀菌活性。我们确定了 HBC 在体内预防 ETEC 感染可能涉及的免疫成分和抗菌活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology 医学-传染病学
CiteScore
2.88
自引率
0.00%
发文量
0
审稿时长
1.5 months
期刊介绍: Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信